REMI BARBIER is President, CEO and Chairman of Pain Therapeutics, Inc.
Prior to PTI, Mr. Barbier helped in the growth or founding of: Exelixis
Inc., a functional genomics company; ArQule, a chemistry company; and
EnzyMed (now owned by Albany Molecular Research), a chemistry company.
Mr. Barbier served as Chief Operating Officer of Exelixis. Prior to
that, he was Vice President of Corporate Development and Clinical
Project Manager of Xoma Corporation, a biotechnology company. Mr.
Barbier received his BA from Oberlin College and his MBA from the
University of Chicago. Profile
TWST: What has gone on at Pain Therapeutics since we spoke last?
Mr. Barbier: Before discussing that, perhaps we should remind people
what we do. We develop new and improved painkillers.